Corcept Therapeutics
NasdaqCM:CORT Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 59 Fair Values set on narratives written by author
GI
Giuca
Community Contributor
Corcept and its fair value according my DCF valuation
Ottima azienda solida finanziariamente senza debiti a lungo e breve termine. Il FcF tende a diminuire nel tempo mentre aumentano i compensi per i vari membri del board che hanno uno skill in the game moderato.
View narrativeUS$63.53
FV
0.02% overvalued intrinsic discount19.41%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
5 months ago author updated this narrative
WA
Consensus Narrative from 4 Analysts
Phase III Success Will Broaden Relacorilant's Use In Treating Cushing Syndrome And Cancer
Key Takeaways Successful Phase III studies suggest significant future revenue growth by expanding the treatment market and raising physician awareness. Promising trials in new therapeutic areas could diversify revenue streams and increase long-term earnings stability.
View narrativeUS$74.90
FV
15.2% undervalued intrinsic discount25.86%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
24 days ago author updated this narrative